Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
NCT06635850Phase 2Active, not recruiting
- Sponsor
- Pulmovant
- Start
- Oct 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 2, randomised, double-blind trial in Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD) comparing Mosliciguat with Matched Placebo (2 arms). Primary endpoint: Pulmonary Vascular Resistance at 16 weeks. Started Oct 2024; status: active, not recruiting.
02
Drugs
mosliciguat
03
Conditions
Pulmonary Hypertension Due To Interstitial Lung Disease (PH-ILD)
Beyond the preview
Go deeper on NCT06635850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06635850.